According to the lawsuit filed Oct. 7, Joseph Chiao, MD, headed research in HAE at CSL for three years and played a key role in developing its marketing strategy.
CSL’s lawsuit claims Dr. Chiao was recruited by Pharming to help it dominate the market for hereditary angioedema drugs, which are used to treat a disease that causes pain and swelling. CSL also sought an injunction to prevent Dr. Chiao from starting work at Pharming.
A federal judge issued an order Oct. 8 preventing Dr. Chiao from being involved in any HAE research and ordered him to return to CSL all stolen documents. It also instructed Pharming not to use any confidential information it may have received.
Pharming issued a statement Oct. 16 saying it “did not induce or encourage Dr. Chiao to breach any rules or contract terms or in any way to remove any data from his former employer.”
Pharming also claims it didn’t see any proprietary information from CSL.
Dr. Chiao has been suspended from Pharming pending the outcome of an upcoming court hearing to resolve the issue.
Read the full article here.
More articles on pharmacy:
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.